Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P14784 (
IL-2 receptor
)
3,849
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Some recently defined lymphocyte immunophenotypes were determined in lesions of patients with American cutaneous leishmaniasis (ACL). New monoclonal antibodies have allowed the demonstration of cell surface antigens of T lymphocytes, such as CD45RA and CD45RO, which recognize different maturational stages of the same T CD4+ cell subgroup: 'virgin' (CD4+CD45RA+) and 'memory' (CD4+CD45RO+) T cells respectively. The CD4/CD8 cell ratios were higher in mucocutaneous leishmaniasis (MCL) than in localized cutaneous leishmaniasis (LCL) lesions.
Diffuse cutaneous leishmaniasis
(
DCL
) has the highest values of 'virgin' T cells; LCL and MCL patients have lower values, similar to each other. 'Memory' T cells were higher in MCL than in LCL or
DCL
. The ratio of 'memory'/'virgin' T cells was 7.9 for LCL, 9.6 for MCL and 2.5 for
DCL
. The highest value for
IL-2 receptor
positive cells (CD25) was observed in LCL, whereas single CD45RO-immunoreactive cells showed a peak value in
DCL
patients. HLA-DR+ cells were present in all three clinical forms of ACL. MCL patients showed a lack of epithelial Langerhans cell (CD1a+) in the nasal mucosa.
...
PMID:Immunocytochemical characterization of immune cells in lesions of American cutaneous leishmaniasis using novel T cell markers. 168 61
Diffuse Cutaneous Leishmaniasis
(
DCL
) is a rare complication of Leishmania aethiopica-induced cutaneous leishmaniasis which is associated with non-self healing and in vivo and in vitro antigen-specific non-responsiveness. Such antigen-specific unresponsiveness is also observed in visceral leishmaniasis (VL). The non-responsiveness seen in VL disease is believed to be due, in part, to serum-derived factors, including raised serum soluble
IL-2 receptor
(sIL-2R). Raised sIL-2R in serum was not a consistent feature of
DCL
in our study (range: 787-4546 U/ml) but was frequently observed in sera of patients with other dermatological disorders (range: 474-3313 U/ml) and some patients with the simple local cutaneous leishmaniasis (LCL; range: 556-4247 U/ml). The level of sIL-2R in the sera of
DCL
patients was not indicative of the disease state. Sera from
DCL
patients did not reduce proliferation of the IL-2-dependent CTLL cell line nor reduce PHA-driven mononuclear cell proliferation, although sera from VL patients could. Both
DCL
and VL sera could reduce the L. aethiopica-driven proliferation. Furthermore addition of serial dilutions of recombinant IL-2 to CTLL cultured in VL or
DCL
sera containing high sIL-2R levels did not alter the effect of such sera on proliferation. We conclude therefore, that raised sIL-2R in serum is not associated with the immunosuppression in
DCL
.
...
PMID:High serum-soluble interleukin-2 receptor is not associated with the immunosuppression in diffuse cutaneous leishmaniasis. 819 Dec 26